A pediatric study of Durasert three-year treatment for posterior segment uveitis.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluocinolone acetonide (Primary)
Indications Posterior uveitis
Focus Therapeutic Use

Most Recent Events

28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
13 Feb 2017 New trial record
07 Feb 2017 According to a pSivida media release, the Company is in discussions with the European regulatory authority on the final design of this trial and expects to file the application in the second quarter of calendar 2017.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight